Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

PURPOSE: Pegfilgrastim is a pegylated form of filgrastim, a recombinant protein of granulocyte colony-stimulating factor, that is used to reduce the risk of febrile neutropenia (FN). Here, we report the results of a phase III trial of pegfilgrastim in breast cancer patients receiving docetaxel and c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Support Care Cancer
Glavni autori: Kosaka, Yoshimasa, Rai, Yoshiaki, Masuda, Norikazu, Takano, Toshimi, Saeki, Toshiaki, Nakamura, Seigo, Shimazaki, Ryutaro, Ito, Yoshinori, Tokuda, Yutaka, Tamura, Kazuo
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2015
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4381099/
https://ncbi.nlm.nih.gov/pubmed/25576433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-014-2597-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items